Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 700 Chesapeake Dr REDWOOD CITY CA 94063 |
Tel: | N/A |
Website: | https://pulmonx.com |
IR: | See website |
Key People | ||
Steven S. Williamson President, Chief Executive Officer, Director | Mehul Joshi Chief Financial Officer, Principal Financial and Chief Accounting Officer | David A. Lehman General Counsel | Geoffrey Beran Rose Chief Commercial Officer |
Business Overview |
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials. |
Financial Overview |
For the three months ended 31 March 2024, Pulmonx Corp revenues increased 30% to $18.9M. Net loss decreased 13% to $13.7M. Revenues reflect United States segment increase of 38% to $12.9M, Europe, Middle-East and Africa ("EMEA") segment increase of 13% to $5.1M. Lower net loss reflects Interest income increase of 28% to $1.4M (income), Foreign Exchange Gain/LossNon-Business increase from $100K to $400K (income). |
Employees: | 279 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $145.07M as of Mar 31, 2024 |
Annual revenue (TTM): | $72.99M as of Mar 31, 2024 |
EBITDA (TTM): | -$58.52M as of Mar 31, 2024 |
Net annual income (TTM): | -$58.73M as of Mar 31, 2024 |
Free cash flow (TTM): | -$37.96M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 38,815,760 as of Apr 30, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |